Search clinical trials for: TR-701 FA Placebo with PSE

Total 36 results

Trius Therapeutics LLC

Completed

A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response

Healthy Subjects

United States
Trius Therapeutics LLC

Completed

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

Renal Impairment

United States
Trius Therapeutics LLC

Completed

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

Bacterial Infection

United States
Trius Therapeutics LLC

Completed

Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients

Bacterial Infection
Trius Therapeutics LLC

Completed

A PK and Safety Study in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Trius Therapeutics LLC

Completed

Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects

Healthy Subjects

United States
Trius Therapeutics LLC

Completed

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) (IV/SAD/MAD)

Bacterial Infections

United States
Trius Therapeutics LLC

Completed

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

Healthy Volunteer

United States
Trius Therapeutics LLC

Completed

A Phase 1, Open-Label, 10 Day Safety Study

Healthy Subjects

United States
Trius Therapeutics LLC

Completed

TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. (ABSSSI)

Skin and Subcutaneous Tissue Bacterial Infections

United States, Argentina, Brazil, Canada, Czechia, Germany, Hungary, Latvia, Peru, Slovakia, Ukraine
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

Acute Bacterial Skin and Skin Structure Infections

United States, Brazil, Bulgaria, Georgia, Germany, Guatemala, Latvia, Lithuania, Mexico, Poland, Russian Federation, South Africa, Turkey, Ukraine
Trius Therapeutics LLC

Completed

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Skin and Subcutaneous Tissue Bacterial Infections

United States, Argentina, Australia, Brazil, Germany, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain
Trius Therapeutics LLC

Completed

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

Healthy Volunteers

United States
Cubist Pharmaceuticals LLC

Completed

Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)

Pneumonia
Merck Sharp & Dohme LLC

Completed

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Gram-Positive Bacterial Infections
Terran Biosciences Australia Pty Ltd

Recruiting

A Study of Idazoxan in Healthy Participants

Healthy

Australia
Pharmasaga Co. Ltd.

Recruiting

Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects

Type II Diabetes

Taiwan
Trius Therapeutics LLC

Completed

Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults (SAD/MAD)

Healthy Subjects

United States
Massachusetts General Hospital

Withdrawn

A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors

Keratosis | Keratosis, Actinic | Skin Neoplasms
SFJ Pharmaceuticals, Inc.
SFJ Pharmaceuticals, Inc.

Terminated

Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers

Healthy

China
Columbia University

Completed

Auriculotherapy During Medication Abortion

Abortion Early

United States
Beth Israel Deaconess Medical Center
OpenBiome

Completed

A Study to Evaluate Fecal Microbiota Transplantation Engraftment in IBS

Irritable Bowel Syndrome

United States
Distribuidora Biolife SA de CV

Recruiting

Efficacy of Nano-Pso Therapy in Menopause

Menopause | Vasomotor; Syndrome

Mexico
Galderma R&D

Completed

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma

Basal Cell Carcinoma

Australia
Halozyme Therapeutics

Completed

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) (HALO-117-406)

Type 1 Diabetes Mellitus

United States
Novartis Pharmaceuticals

Completed

A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

Episodic Migraine

Austria, Belgium, Italy, Spain, Germany, Sweden, Czechia, Netherlands, France, Denmark, Switzerland, United Kingdom, Greece, Finland, Australia, Norway
EpicentRx, Inc.

Completed

RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1)

Glioblastoma | Oligodendroglioma | Anaplastic Oligodendroglioma

United States
University of North Carolina, Chapel Hill
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Human Requirements for the Nutrient Choline

Postmenopausal Women

United States
University of Tennessee

Terminated

TAP Block With Liposomal Bupivacaine Versus Pre-incisional Wound Infiltration With Bupivacaine for Postoperative Pain (LATAP)

Postoperative Pain
Pfizer

Completed

Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)

Healthy

Canada
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Glioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain Neoplasm

United States, Canada
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Metastatic Prostate Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Renal... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; North Central...

Active, not recruiting

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Breast Adenocarcinoma

United States, Peru, South Africa

Search clinical trials for: TR-701 FA Placebo with PSE

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations